Literature DB >> 7047560

In vitro evaluation of CENTA, a new beta-lactamase-susceptible chromogenic cephalosporin reagent.

R N Jones, H W Wilson, W J Novick, A L Barry, C Thornsberry.   

Abstract

CENTA is a newly synthesized, beta-lactamase-labile, chromogenic cephalosporin reagent which changes color from light yellow (lambda maximum ca. 340 nm) to chrome yellow (lambda maximum ca. 405 nm) concomitant with hydrolysis of the beta-lactam ring. This compound offers promise as a diagnostic reagent comparable to other chromogens (PADAC and nitrocefin) for the early detection of beta-lactamase-producing clinical isolates, while retaining some antimicrobial effect against Escherichia coli, Klebsiella spp., Proteus mirabilis, Staphylococcus aureus, and non-enterococcal Streptococcus spp. CENTA is relatively unaffected by commonly used microbiological media and human serum.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7047560      PMCID: PMC272221          DOI: 10.1128/jcm.15.5.954-958.1982

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  10 in total

1.  Partial characterization of a beta-lactamase from Vibrio parahaemolyticus by a new automated microiodometric technique.

Authors:  R M DeBell; T M Hickey; D E Uddin
Journal:  Antimicrob Agents Chemother       Date:  1978-02       Impact factor: 5.191

2.  Novel R-plasmid-mediated beta-lactamase from Klebsiella aerogenes.

Authors:  V Petrocheilou; R B Sykes; M H Richmond
Journal:  Antimicrob Agents Chemother       Date:  1977-07       Impact factor: 5.191

Review 3.  The beta-lactamases of gram-negative bacteria and their possible physiological role.

Authors:  M H Richmond; R B Sykes
Journal:  Adv Microb Physiol       Date:  1973       Impact factor: 3.517

4.  [An enzymic method for the determination of cefotaxim in serum and urine (author's transl)].

Authors:  G Seibert; A Biebach
Journal:  J Clin Chem Clin Biochem       Date:  1981-05

5.  Transferable multiple antibiotic resistance in Haemophilus influenzae.

Authors:  V O Rotimi; D C Turk
Journal:  J Antimicrob Chemother       Date:  1981-09       Impact factor: 5.790

6.  The comparative beta-lactamase resistance and inhibitory activity of 1-oxa cephalosporin, cefoxitin and cefotaxime.

Authors:  K P Fu; H C Neu
Journal:  J Antibiot (Tokyo)       Date:  1979-09       Impact factor: 2.649

7.  Interaction of a new cephalosporin, 7-cyanacetamidocephalosporanic acid, with some gram-negative and gram-positive beta-lactamase-producing bacteria.

Authors:  A D Russel
Journal:  Antimicrob Agents Chemother       Date:  1972-10       Impact factor: 5.191

8.  In vitro evaluation of pyridine-2-azo-p-dimethylaniline cephalosporin, a new diagnostic chromogenic reagent, and comparison with nitrocefin, cephacetrile, and other beta-lactam compounds.

Authors:  R N Jones; H W Wilson; W J Novick
Journal:  J Clin Microbiol       Date:  1982-04       Impact factor: 5.948

9.  Novel method for detection of beta-lactamases by using a chromogenic cephalosporin substrate.

Authors:  C H O'Callaghan; A Morris; S M Kirby; A H Shingler
Journal:  Antimicrob Agents Chemother       Date:  1972-04       Impact factor: 5.191

10.  In vitro antimicrobial activity evaluation of cefodizime (HR221), a new semisynthetic cephalosporin.

Authors:  R N Jones; A L Barry; C Thornsberry; H W Wilson
Journal:  Antimicrob Agents Chemother       Date:  1981-12       Impact factor: 5.191

  10 in total
  17 in total

1.  CENTA as a chromogenic substrate for studying beta-lactamases.

Authors:  C Bebrone; C Moali; F Mahy; S Rival; J D Docquier; G M Rossolini; J Fastrez; R F Pratt; J M Frère; M Galleni
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  Novel beta-lactamase-random peptide fusion libraries for phage display selection of cancer cell-targeting agents suitable for enzyme prodrug therapy.

Authors:  Girja S Shukla; David N Krag
Journal:  J Drug Target       Date:  2010-02       Impact factor: 5.121

3.  Cancer cell-specific internalizing ligands from phage displayed beta-lactamase-peptide fusion libraries.

Authors:  Girja S Shukla; David N Krag
Journal:  Protein Eng Des Sel       Date:  2010-03-10       Impact factor: 1.650

4.  Phage-displayed combinatorial peptide libraries in fusion to beta-lactamase as reporter for an accelerated clone screening: Potential uses of selected enzyme-linked affinity reagents in downstream applications.

Authors:  Girja S Shukla; David N Krag
Journal:  Comb Chem High Throughput Screen       Date:  2010-01       Impact factor: 1.339

5.  Relation between beta-lactamase production and antimicrobial activity: comparison of the new compound HR 810 with cefotaxime.

Authors:  W Cullmann; W Opferkuch; M Stieglitz
Journal:  Eur J Clin Microbiol       Date:  1983-08       Impact factor: 3.267

6.  Type II secretion by Aeromonas salmonicida: evidence for two periplasmic pools of proaerolysin.

Authors:  S E Burr; D B Diep; J T Buckley
Journal:  J Bacteriol       Date:  2001-10       Impact factor: 3.490

7.  High-throughput screening of amastigotes of Leishmania donovani clinical isolates against drugs using a colorimetric beta-lactamase assay.

Authors:  Swati Mandal; Mahendra Maharjan; Sudipto Ganguly; Mitali Chatterjee; Sarman Singh; Frederick S Buckner; Rentala Madhubala
Journal:  Indian J Exp Biol       Date:  2009-06       Impact factor: 0.818

8.  Evidence for nonspecific induction of beta-lactamase in overproducing variants of Enterobacter cloacae and Citrobacter freundii.

Authors:  W Cullmann; W Dick
Journal:  Eur J Clin Microbiol       Date:  1985-02       Impact factor: 3.267

9.  Detection of resistance due to inducible beta-lactamase in Enterobacter aerogenes and Enterobacter cloacae.

Authors:  T W Huber; J S Thomas
Journal:  J Clin Microbiol       Date:  1994-10       Impact factor: 5.948

10.  Evaluation of two methods for rapid testing for beta-lactamase production in Bacteroides and Fusobacterium.

Authors:  P C Appelbaum; S K Spangler; M R Jacobs
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-01       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.